564 related articles for article (PubMed ID: 20653676)
1. CYP4F2 rs2108622: a minor significant genetic factor of warfarin dose in Han Chinese patients with mechanical heart valve replacement.
Cen HJ; Zeng WT; Leng XY; Huang M; Chen X; Li JL; Huang ZY; Bi HC; Wang XD; He YL; He F; Zhou RN; Zheng QS; Zhao LZ
Br J Clin Pharmacol; 2010 Aug; 70(2):234-40. PubMed ID: 20653676
[TBL] [Abstract][Full Text] [Related]
2. Impact of CYP2C9*3, VKORC1-1639, CYP4F2rs2108622 genetic polymorphism and clinical factors on warfarin maintenance dose in Han-Chinese patients.
Liang R; Li L; Li C; Gao Y; Liu W; Hu D; Sun Y
J Thromb Thrombolysis; 2012 Jul; 34(1):120-5. PubMed ID: 22528326
[TBL] [Abstract][Full Text] [Related]
3. Impact of VKORC1, CYP4F2 and NQO1 gene variants on warfarin dose requirement in Han Chinese patients with catheter ablation for atrial fibrillation.
Li J; Yang W; Xie Z; Yu K; Chen Y; Cui K
BMC Cardiovasc Disord; 2018 May; 18(1):96. PubMed ID: 29776386
[TBL] [Abstract][Full Text] [Related]
4. Genetic polymorphisms of VKORC1, CYP2C9, CYP4F2 in Bai, Tibetan Chinese.
Zeng WT; Zheng QS; Huang M; Cen HJ; Lai Y; Chen WY; Zhao LZ; Leng XY
Pharmazie; 2012 Jan; 67(1):69-73. PubMed ID: 22393834
[TBL] [Abstract][Full Text] [Related]
5. A new algorithm to predict warfarin dose from polymorphisms of CYP4F2 , CYP2C9 and VKORC1 and clinical variables: derivation in Han Chinese patients with non valvular atrial fibrillation.
Wei M; Ye F; Xie D; Zhu Y; Zhu J; Tao Y; Yu F
Thromb Haemost; 2012 Jun; 107(6):1083-91. PubMed ID: 22534826
[TBL] [Abstract][Full Text] [Related]
6. Cytochrome P450 oxidoreductase genetic polymorphisms A503V and rs2868177 do not significantly affect warfarin stable dosage in Han-Chinese patients with mechanical heart valve replacement.
Tan SL; Li Z; Zhang W; Song GB; Liu LM; Peng J; Liu ZQ; Fan L; Meng XG; Wang LS; Chen Y; Zhou XM; Zhou HH
Eur J Clin Pharmacol; 2013 Oct; 69(10):1769-75. PubMed ID: 23949431
[TBL] [Abstract][Full Text] [Related]
7. Influence of warfarin dose-associated genotypes on the risk of hemorrhagic complications in Chinese patients on warfarin.
Ma C; Zhang Y; Xu Q; Yang J; Zhang Y; Gao L; Xu B; Wang H; Li Y; Lu C; Yin T
Int J Hematol; 2012 Dec; 96(6):719-28. PubMed ID: 23104259
[TBL] [Abstract][Full Text] [Related]
8. Impact of genetic factors (CYP2C9, VKORC1 and CYP4F2) on warfarin dose requirement in the Turkish population.
Özer M; Demirci Y; Hizel C; Sarikaya S; Karalti İ; Kaspar Ç; Alpan S; Genç E
Basic Clin Pharmacol Toxicol; 2013 Mar; 112(3):209-14. PubMed ID: 23061746
[TBL] [Abstract][Full Text] [Related]
9. CYP4F2 gene polymorphism as a contributor to warfarin maintenance dose in Japanese subjects.
Nakamura K; Obayashi K; Araki T; Aomori T; Fujita Y; Okada Y; Kurabayashi M; Hasegawa A; Ohmori S; Nakamura T; Yamamoto K
J Clin Pharm Ther; 2012 Aug; 37(4):481-5. PubMed ID: 22172097
[TBL] [Abstract][Full Text] [Related]
10. Influence of CYP4F2 rs2108622 (V433M) on warfarin dose requirement in Asian patients.
Singh O; Sandanaraj E; Subramanian K; Lee LH; Chowbay B
Drug Metab Pharmacokinet; 2011; 26(2):130-6. PubMed ID: 21084764
[TBL] [Abstract][Full Text] [Related]
11. Effect of CYP2C9 and VKORC1 genotypes on early-phase and steady-state warfarin dosing in Korean patients with mechanical heart valve replacement.
Kim HS; Lee SS; Oh M; Jang YJ; Kim EY; Han IY; Cho KH; Shin JG
Pharmacogenet Genomics; 2009 Feb; 19(2):103-12. PubMed ID: 19077919
[TBL] [Abstract][Full Text] [Related]
12. Effect of CYP2C9, VKORC1, CYP4F2 and GGCX genetic variants on warfarin maintenance dose and explicating a new pharmacogenetic algorithm in South Indian population.
Krishna Kumar D; Shewade DG; Loriot MA; Beaune P; Balachander J; Sai Chandran BV; Adithan C
Eur J Clin Pharmacol; 2014 Jan; 70(1):47-56. PubMed ID: 24019055
[TBL] [Abstract][Full Text] [Related]
13. Responsiveness to low-dose warfarin associated with genetic variants of VKORC1, CYP2C9, CYP2C19, and CYP4F2 in an Indonesian population.
Rusdiana T; Araki T; Nakamura T; Subarnas A; Yamamoto K
Eur J Clin Pharmacol; 2013 Mar; 69(3):395-405. PubMed ID: 22855348
[TBL] [Abstract][Full Text] [Related]
14. Integrating interacting drugs and genetic variations to improve the predictability of warfarin maintenance dose in Chinese patients.
Zhong SL; Yu XY; Liu Y; Xu D; Mai LP; Tan HH; Lin QX; Yang M; Lin SG
Pharmacogenet Genomics; 2012 Mar; 22(3):176-82. PubMed ID: 22198820
[TBL] [Abstract][Full Text] [Related]
15. Genetic factors associated with patient-specific warfarin dose in ethnic Indonesians.
Suriapranata IM; Tjong WY; Wang T; Utama A; Raharjo SB; Yuniadi Y; Tai SS
BMC Med Genet; 2011 Jun; 12():80. PubMed ID: 21639946
[TBL] [Abstract][Full Text] [Related]
16. [Impact of six genetic polymorphisms on Warfarin maintenance dose variation in Chinese Han population].
Lou Y; Han L; Li Y; Zhang X; Liu Z; Tang M; Yu H; Wang W; Xu J; Liu H; Li Y
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2014 Jun; 31(3):367-71. PubMed ID: 24928022
[TBL] [Abstract][Full Text] [Related]
17. The influence of CYP2C9 and VKORC1 gene polymorphisms on optimal warfarin doses after heart valve replacement.
Tatarūnas V; Lesauskaitė V; Veikutienė A; Jakuška P; Benetis R
Medicina (Kaunas); 2011; 47(1):25-30. PubMed ID: 21681008
[TBL] [Abstract][Full Text] [Related]
18. VKORC1-1639G>A, CYP2C9, EPHX1691A>G genotype, body weight, and age are important predictors for warfarin maintenance doses in patients with mechanical heart valve prostheses in southwest China.
Gu Q; Kong Y; Schneede J; Xiao YB; Chen L; Zhong QJ; Wang XF; Hao J; Chen BC; Chen JJ
Eur J Clin Pharmacol; 2010 Dec; 66(12):1217-27. PubMed ID: 20842355
[TBL] [Abstract][Full Text] [Related]
19. Estimation of the warfarin dose with a pharmacogenetic refinement algorithm in Chinese patients mainly under low-intensity warfarin anticoagulation.
Xu Q; Xu B; Zhang Y; Yang J; Gao L; Zhang Y; Wang H; Lu C; Zhao Y; Yin T
Thromb Haemost; 2012 Dec; 108(6):1132-40. PubMed ID: 23015069
[TBL] [Abstract][Full Text] [Related]
20. The impact of non-genetic and genetic factors on a stable warfarin dose in Thai patients.
Wattanachai N; Kaewmoongkun S; Pussadhamma B; Makarawate P; Wongvipaporn C; Kiatchoosakun S; Vannaprasaht S; Tassaneeyakul W
Eur J Clin Pharmacol; 2017 Aug; 73(8):973-980. PubMed ID: 28550460
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]